Roche: High-Dose Ocrevus Falls Short of Primary Endpoint in Relapsing Multiple Sclerosis Trial

In the Phase III MUSETTE study, a higher dose of intravenous Ocrevus (ocrelizumab) did not provide additional benefit in slowing disability progression compared to the currently approved 600mg dose.